5,335 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Purchased by Toth Financial Advisory Corp

Toth Financial Advisory Corp bought a new position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 5,335 shares of the biotechnology company's stock, valued at approximately $832,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Legato Capital Management LLC boosted its holdings in shares of Ascendis Pharma A/S by 7.5% in the 4th quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company's stock valued at $264,000 after buying an additional 134 shares in the last quarter. Blue Trust Inc. lifted its position in Ascendis Pharma A/S by 415.2% during the fourth quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 328 shares during the last quarter. Sanctuary Advisors LLC purchased a new stake in Ascendis Pharma A/S during the fourth quarter valued at approximately $203,000. Rice Hall James & Associates LLC boosted its stake in Ascendis Pharma A/S by 2.0% in the fourth quarter. Rice Hall James & Associates LLC now owns 163,888 shares of the biotechnology company's stock valued at $22,562,000 after acquiring an additional 3,274 shares in the last quarter. Finally, New York State Common Retirement Fund grew its holdings in Ascendis Pharma A/S by 14.0% in the fourth quarter. New York State Common Retirement Fund now owns 204,482 shares of the biotechnology company's stock worth $28,151,000 after purchasing an additional 25,164 shares during the last quarter.

Analysts Set New Price Targets

Several equities research analysts have recently commented on ASND shares. Wedbush lifted their price objective on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. Bank of America lifted their price target on Ascendis Pharma A/S from $201.00 to $216.00 and gave the stock a "buy" rating in a research report on Monday. Evercore ISI increased their price objective on Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $200.00 target price on shares of Ascendis Pharma A/S in a report on Monday, May 12th. Finally, Royal Bank of Canada upped their target price on Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. One equities research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, Ascendis Pharma A/S has an average rating of "Moderate Buy" and an average price target of $217.73.

Ascendis Pharma A/S Stock Performance

Shares of ASND traded down $0.80 during trading hours on Tuesday, hitting $172.35. The stock had a trading volume of 380,950 shares, compared to its average volume of 493,473. The firm has a 50-day moving average price of $159.37 and a 200 day moving average price of $147.11. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $183.00. The firm has a market capitalization of $10.51 billion, a price-to-earnings ratio of -24.27 and a beta of 0.37.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The business had revenue of $123.97 million for the quarter, compared to analyst estimates of $98.56 million. As a group, analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.